Clinical Quiz: Nonstatin Therapies for LDL-C Lowering in Special Populations
This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.
Editor’s note: this is the second clinical quiz on the ACC’s 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Check out the first quiz.
In LDL-C management, statins have remained a cornerstone of care since their advent decades ago. However, despite mountains of data demonstrating class's profound effect on LDL-C lowering and favorable safety profile, many patients are statin-intolerant and require a more nuanced approach to the management of their dyslipidemia, especially special patient populations.
Decades ago, this presented a major issue for some, but, in recent years, addition of new therapies, including bempedoic acid and combination with ezetimibe, have proven to be reliable options for these patients. In this clinical quiz, which is our second on the document, we test your knowledge on use of non-statin therapies for lowering LDL-C among special populations based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Why is it important to consider special populations when prescribing nonstatin therapies?
References:
Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in J Am Coll Cardiol. 2023 Jan 3;81(1):104]. J Am Coll Cardiol. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006
